Cargando…
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry
BACKGROUND: With the availability of multiple treatment options for metastatic castration-resistant prostate cancer (mCRPC), new real-world data on disease management and drugs’ performance are needed. METHODS: We described characteristics, management and clinical outcomes of patients receiving firs...
Autores principales: | Galli, Luca, Chiuri, Vincenzo Emanuele, Di Lorenzo, Giuseppe, Pisconti, Salvatore, Rossetti, Sabrina, Sirotova, Zuzana, Muto, Andrea, Petrioli, Roberto, De Tursi, Michele, Sbrana, Andrea, Francolini, Giulio, Ardizzoia, Antonio, Scavelli, Claudio, Satta, Francesco, Quadrini, Silvia, Airoldi, Mario, D’Aniello, Carmine, Bonetti, Andrea, Conforti, Serafino, Aieta, Michele, Beccaglia, Patrizia, Maestri, Antonio, Fratino, Lucia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070548/ https://www.ncbi.nlm.nih.gov/pubmed/35400269 http://dx.doi.org/10.1177/03008916221079662 |
Ejemplares similares
-
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
por: Roviello, Giandomenico, et al.
Publicado: (2019) -
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
por: Procopio, Giuseppe, et al.
Publicado: (2020) -
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study
por: Roviello, Giandomenico, et al.
Publicado: (2018) -
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020) -
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study
por: Verzoni, Elena, et al.
Publicado: (2016)